Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 149Thoracic 13Breast 8Gynecologic 7Genitourinary 7Head & Neck 5Sarcoma 3Dermatologic 3Endocrine 2CNS 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1540Leukemia 1389Precursor Cell Lymphoblastic Leukemia-Lymphoma 1282Leukemia, Lymphocytic, Chronic, B-Cell 1090Myelodysplastic Syndromes 722Lymphoma 658Lymphoma, Non-Hodgkin 627Hematologic Neoplasms 556Lymphoma, Follicular 487Leukemia, Myelogenous, Chronic, BCR-ABL Positive 470Lymphoma, Mantle-Cell 459Lymphoma, Large B-Cell, Diffuse 444Burkitt Lymphoma 432Hodgkin Disease 431Lymphoma, B-Cell, Marginal Zone 424Multiple Myeloma 415Lymphoma, Large-Cell, Immunoblastic 335Leukemia, Myelomonocytic, Chronic 314Congenital Abnormalities 287Recurrence 279Leukemia, Myeloid, Chronic-Phase 272Myeloproliferative Disorders 260Neoplasms 256Blast Crisis 250Waldenstrom Macroglobulinemia 232Leukemia, Myeloid, Accelerated Phase 217Lymphoma, T-Cell, Cutaneous 213Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 208Mycosis Fungoides 183Lymphoma, Large-Cell, Anaplastic 181

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Biliary Tract Neoplasms × Other hematologic neoplasm × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡